...
机译:使用MDA-9 / Syntenin(SDCBP)PDZ1小分子抑制剂抑制前列腺癌的发病机制
Department of Human and Molecular Genetics Virginia Commonwealth University School of Medicine;
Department of Human and Molecular Genetics Virginia Commonwealth University School of Medicine;
Department of Human and Molecular Genetics Virginia Commonwealth University School of Medicine;
Department of Human and Molecular Genetics Virginia Commonwealth University School of Medicine;
Department of Human and Molecular Genetics Virginia Commonwealth University School of Medicine;
Department of Human and Molecular Genetics Virginia Commonwealth University School of Medicine;
Department of Human and Molecular Genetics Virginia Commonwealth University School of Medicine;
Department of Human and Molecular Genetics Virginia Commonwealth University School of Medicine;
Department of Human and Molecular Genetics Virginia Commonwealth University School of Medicine;
Department of Human and Molecular Genetics Virginia Commonwealth University School of Medicine;
机译:使用MDA-9 / Syntenin(SDCBP)PDZ1小分子抑制剂抑制前列腺癌的发病机制
机译:Syntenin1 / MDA-9(SDCBP)通过上调PD-L1诱导三阴性乳腺癌中的免疫逃避
机译:SDCBP / MDA-9 / Syntenin调节Anoikis抗性胶质瘤干细胞的保护性自噬
机译:新的基于小分子的ErbB-2PTK乳腺癌抑制剂的发现
机译:日粮γ-亚麻酸抑制前列腺癌的Lobund-Wistar大鼠模型中的前列腺癌生长。
机译:MDA-9 / Syntenin(SDCBP)是前列腺癌干细胞中化学抑制存活率和茎的临界调节剂
机译:使用MDA-9 / Syntenin(SDCBP)PDZ1小分子抑制剂抑制前列腺癌发病机制
机译:临床前测试有效和新型Bc1-2小分子抑制剂的治疗潜力,作为激素难治性前列腺癌的新疗法;最终的评论。 2004年11月30日至2007年11月29日